Design of a phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis
This trial evaluates the efficacy, safety and dose range of BI 1819479 in patients with IPF, offering a potential additional treatment option, and will establish appropriate dosing for phase III trials.
Authors
- Elisabetta Renzoni (ORCID: https://orcid.org/0000-0002-1118-797X)
- Francesco Bonella (ORCID: https://orcid.org/0000-0001-7579-9767)
- María Molina‐Molina (ORCID: https://orcid.org/0000-0002-1852-1723)
- Haruyuki Ishii (ORCID: https://orcid.org/0000-0002-9435-9246)
- Wim Wuyts (ORCID: https://orcid.org/0000-0001-9648-3497)
- Julia Krzykalla (ORCID: https://orcid.org/0000-0002-5242-9824)
- Susanne Stowasser (ORCID: https://orcid.org/0009-0008-6013-0225)
- Sandra Hadl
- Joyce Lee (ORCID: https://orcid.org/0000-0002-5758-8365)
- Michael Engel (ORCID: https://orcid.org/0000-0003-4662-046X)
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Kyorin University (JP)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Ruhrlandklinik (DE)
- Boehringer Ingelheim (Austria) (AT)
- Boehringer Ingelheim (China) (CN)
- Imperial College London (GB)
- University of Colorado Denver (US)
- KU Leuven (BE)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-11-09
- DOI
- https://doi.org/10.1183/23120541.00973-2025
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00